Vyant Bio (NASDAQ:VYNT) CEO Jay Roberts and new chief scientific officer Robert Fremeau joined Proactive to discuss Fremeau's new appointment.
Roberts and Fremeau discuss the CSO's background and what attracted him to Vyant, adding he is an experienced research and development leader with over two decades of drug discovery experience in academia and industry, advancing next-generation drug development for severe neurological disorders.